Write in a clean editor, then format for Onco in one click — DocuGuru applies the official MDPI template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Onco is a peer-reviewed journal published by MDPI, covering Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Cancer, Hypoxia, and Metabolism. Over its lifetime it has published 172 papers, which have received 400 citations.
| Publisher | MDPI |
|---|---|
| Reference style | Numbered (MDPI) Numbered — [1], [2] in the text 1. Smith, A.; Jones, B.; Lee, C. A Representative Article Title. Onco 2023, 12, 45–58.
Formats any DOI in Onco style. No sign-up. |
| Publishes research in | Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Cancer, Hypoxia, and Metabolism Glioma Diagnosis and Treatment Lung Cancer Treatments and Mutations |
| ISSN | 2673-7523 |
| Citation impact (2-yr) | 1.81 |
| h-index | 8 |
| i10-index | 4 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Harvard University |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The integration of small interfering RNA (siRNA) with traditional cancer therapies represents a promising frontier in oncology aimed at enhancing treatment effectiveness, reducing side effects, and overcoming drug resistance. This review highlights the potential of siRNA to selectively silence genes that are overexpressed or uniquely expressed in cancer cells, thereby disrupting critical pathways that support…
Cancer is one of the leading causes of death worldwide. Multifactorial etiology of cancer and tumor heterogeneity are the two most acute challenges in existing diagnostic and therapeutic strategies for cancer. An effective precision cancer medicine strategy to overcome these challenges requires a clear understanding of the transcriptomic landscape of cancer cells. Recent innovative breakthroughs…
NUP98 fusions constitute a small subgroup of AML patients and remain a high-risk AML subtype. There are approximately thirty types of NUP98 fusion identified in AML patients. These patients show resistance to currently available therapies and poor clinical outcomes. NUP98 fusions with different fusion partners have oncogenic transformation potential. This review describes how the NUP98…
The human epidermal growth factor receptors (HERs) are expressed abundantly in the human body. The tumorigenic potential of HER2/neu is linked to its overexpression, amplification or somatic mutation. The HER2 gene amplification leading to protein overexpression has been reported in 25–30% of breast cancers and 10–30% of gastric/gastroesophageal cancers. While HER2 is a well-documented predictive,…
Cancer, one of the leading causes of death worldwide, is on the rise. The high toxicity of conventional chemotherapy, often applied as drug cocktails, and the development of resistance limit the use of antineoplastic drugs and reduce the quality of life. With easier access, a growing number of patients are using cannabis (cannabinoids) for alleviation…
